Lymph Nodes Mapping with a Novel Long-lasting Evans Blue
Rui Tian,Qiao Zeng,Lixin Lang,Ying Ma,Orit Jacobson,Xiao Fu,Guizhi Zhu,Dale Kiesewetter,Gang Liu,Gang Niu,Xiaoyuan Chen
2018-01-01
Journal of Nuclear Medicine
Abstract:190 Objectives: Evans blue dye shows reversible binding with serum albumin and a series of Evan blue derivatives (NEB) have been developed for blood pool imaging, lymphatic mapping, and tumor theranostics. After local injection, NEB forms complexes with endogenous albumin in the interstitial fluid and allow for visualizing the lymphatic system. However, leakage of signal from lymphatic system to blood circulating system could be observed due to low binding affinity and relatively small size of NEB-albumin complex. In order to overcome this problem, in this study, we developed a new tracer, named N(EB)2, which has two albumin binding moieties, for lymph node mapping using multimodal imaging. Material and methods: A series of N(EB)2 with different lengths were synthesized after rational design using docking simulation. The binding features of N(EB)2 with albumin were characterized with Atomic Force Microscopy, Transmission Electron Microscopy, high resolution Liquid Chromatography-Mass Spectrometry, Dynamic Light Scattering, and Bio-Layer Interferometry. In vivo pharmacokinetics, lymphatic mapping and tumor imaging of N(EB)2 were evaluated to compare with NEB after F-18 and Cu-64 labeling. Results: With two albumin binding moieties, N(EB)2 can attach two albumins with lower free energy. The dimerization was confirmed by AFM, DLS and TEM. N(EB)2 showed a significantly increased binding affinity with albumin and an extended half-life in circulation compared with NEB. Consequently, N(EB)2 migrates slower in lymphatic vessels to induce a preferable time-window between the sentinel lymph node (SLN) and secondary lymph node for better differentiation. In addition, N(EB)2 showed significantly enhanced tumor retention compared with NEB, especially at late time points (at 24h, and 48h p.i.). Conclusion: Via increased albumin binding affinity and dimerization, N(EB)2 was proved to be an optimized tracer for lymphatic mapping. The easy labeling and multimodal ability make it a potential candidate for clinical translation.